致：香港交易及結算所有限公司 公司名稱: 盈健醫療集團有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01419 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 100,000,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上 ...

Group 1 - The core stock price of Yingjian Medical (01419.HK) closed at HKD 1.110 on August 13, down 1.77% from the previous trading day, with an intraday high of HKD 1.160, marking a nearly one-year high [1] - The company experienced a net inflow of HKD 17.59 thousand on that day, with unspecified amounts flowing in and out [1] - Yingjian Medical Group Limited, established in 1997, is one of the largest medical groups in Hong Kong, listed on the Hong Kong Stock Exchange under stock code 1419 [1] Group 2 - The group operates under the brands "Human Health Integrated Medical Centre," "Human Health Medical Centre," and "Perfect Life," providing comprehensive primary healthcare services [1] - Yingjian Medical has over 60 medical centers across Hong Kong, Kowloon, the New Territories, and outlying islands, offering a wide range of services including prevention, health maintenance, diagnosis, and treatment [1] - The company aims to expand its network of medical centers and establish specialized medical service centers, adhering to its corporate culture of "benevolence" to ensure more citizens can access quality healthcare services [1]

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

8月12日，截至港股收盘，恒生指数上涨0.25%，报24969.68点。盈健医疗（01419.HK）收报1.13港元/ 股，上涨11.88%，成交量130万股，成交额141.04万港元，振幅14.85%。 最近一个月来，盈健医疗累计涨幅20.24%，今年来累计涨幅29.49%，跑赢恒生指数24.16%的涨幅。 财务数据显示，截至2024年12月31日，盈健医疗实现营业总收入2.92亿元，同比增长6.98%；归母净利 润1557.78万元，同比减少16.03%；毛利率47.09%，资产负债率25.1%。 资料显示，盈健医疗集团有限公司成立于1997年,在香港联合交易所上市(股份代号:1419),是香港最大型 的医疗集团之一。本集团以'盈健综合医务中心(Human Health Integrated Medical Centre)'、'盈健医务中 心(Human Health Medical Centre)'及'优越医疗(PerfectLife)'品牌提供全科医疗服务。集团开设逾60间医 务中心,网络遍布港九新界及离岛。 集团为个人及企业团体提供全面的医疗服务,服务范围涵盖预防、保健、诊症及治疗;门诊更是病人与整 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 盈健醫療集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01419 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/ ...

7月23日，截至港股收盘，恒生指数上涨1.62%，报25538.07点。盈健医疗（01419.HK）收报0.98港元/ 股，上涨13.95%，成交量109.4万股，成交额101.21万港元，振幅15.12%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-1.96倍，行业中值1.36倍。盈健医疗 市盈率15.56倍，行业排名第25位；其他巨星医疗控股（02393.HK）为0.33倍、京玖康疗（00648.HK） 为0.38倍、医汇集团（08161.HK）为2.35倍、瑞慈医疗（01526.HK）为5.3倍、环球医疗（02666.HK） 为5.38倍。 资料显示，盈健医疗集团有限公司成立于1997年,在香港联合交易所上市(股份代号:1419),是香港最大型 的医疗集团之一。本集团以'盈健综合医务中心(Human Health Integrated Medical Centre)'、'盈健医务中 心(Human Health Medical Centre)'及'优越医疗(PerfectLife)'品牌提供全科医疗服务。集团开设逾60间医 务中心, ...

Revenue Performance - The company's revenue for the first half of the fiscal year 2025 was approximately HKD 315.8 million, an increase of about HKD 20.6 million or 7.0% compared to the same period in fiscal year 2024[10]. - Revenue from primary healthcare services increased by approximately HKD 7.7 million or 3.9% to about HKD 206.6 million, driven by an increase in patient visits[11]. - Revenue from specialist medical services rose by approximately HKD 16.1 million or 24.7% to about HKD 81.3 million, attributed to increased patient visits despite a decrease in average spending per visit[11]. - Revenue from dental services decreased by approximately HKD 3.2 million or 10.2% to about HKD 27.9 million, mainly due to a reduction in average spending per visit[11]. - The revenue from the specialist medical division increased to approximately HKD 81.3 million, representing a year-on-year growth of about 24.7%[35]. - The revenue from the general medical division grew by approximately 3.9% compared to the mid-term of fiscal year 2024[33]. - The dental services revenue decreased to approximately HKD 27.9 million from HKD 31.1 million in the mid-term of fiscal year 2024, reflecting market challenges[36]. - Total revenue for the six months ended December 31, 2024, was HKD 315,788,000, an increase of 6.7% compared to HKD 295,190,000 in the same period of 2023[140]. - General medical services revenue reached HKD 206,609,000, up 3.4% from HKD 198,929,000 year-on-year[140]. - Specialist medical services revenue increased by 24.7% to HKD 81,256,000 from HKD 65,152,000[140]. - Dental services revenue decreased by 10.3% to HKD 27,923,000 compared to HKD 31,109,000 in the previous year[140]. Profitability and Margins - The company's net profit for the mid-term of fiscal year 2025 decreased to approximately HKD 16.8 million, a reduction of about HKD 3.2 million or 16.0% compared to the mid-term of fiscal year 2024[27]. - The net profit margin declined from approximately 6.8% in the mid-term of fiscal year 2024 to about 5.3% in the mid-term of fiscal year 2025[27]. - Gross profit increased by approximately HKD 8.2 million or 5.8% to about HKD 148.7 million, with a slight decrease in gross margin from 47.6% to 47.1%[14]. - The gross margin for primary healthcare services decreased from 55.7% to 54.5%, while the gross margin for specialist services increased from 25.7% to 29.7%[19]. - Basic and diluted earnings per share were both HKD 0.044, down from HKD 0.053 in the prior year, reflecting a decline of 16.9%[113]. - Adjusted profit before tax for the six months was HKD 20,066,000, down 16.1% from HKD 23,934,000 in the prior period[142]. - The net profit for the period was HKD 16,822,000, a decrease of 16.5% from HKD 20,033,000 in the previous year[113]. Costs and Expenses - The cost of services provided increased by approximately HKD 12.4 million or 8.0% to about HKD 167.1 million, primarily due to increased doctor fees related to higher revenue from healthcare services[13]. - Administrative and other expenses increased by approximately HKD 6.8 million or 5.6% to about HKD 128.9 million, mainly due to an increase in employee costs[22]. - Total costs of services provided amounted to HKD 167,070,000, an increase from HKD 154,684,000, reflecting a rise in medical supplies and personnel costs[142]. Financial Position - The company reported a net asset value of HKD 771,370,000 as of December 31, 2024, compared to HKD 766,666,000 as of June 30, 2024, reflecting a slight increase of 0.9%[116]. - Total assets as of December 31, 2024, were HKD 1,046,852,000, compared to HKD 1,056,373,000 as of June 30, 2024[114]. - Current assets totaled HKD 610,545,000, slightly down from HKD 613,614,000 at the end of the previous period[114]. - Current liabilities decreased to HKD 193,398,000 from HKD 215,820,000, showing a reduction of 10.4%[114]. - The company’s total non-current liabilities decreased to HKD 65,084,000 as of December 31, 2024, down from HKD 73,887,000 as of June 30, 2024, a reduction of 11.9%[116]. - The company’s cash and cash equivalents increased to HKD 397,626,000 as of December 31, 2024, from HKD 184,207,000 a year earlier, marking a substantial increase of 116.5%[125]. - The company generated a net cash inflow from investing activities of HKD 268,483,000 for the six months ended December 31, 2024, compared to HKD 19,220,000 in the prior year[122]. Strategic Initiatives - The company plans to enhance its position in the dental services market through the acquisition of Youde Dental Clinic, announced on January 3, 2025[36]. - The board maintains a cautiously optimistic outlook for the second half of the fiscal year 2025, recognizing the need to adapt to market changes and seize growth opportunities[57]. - The group has actively explored strategic growth and revenue diversification, aiming to expand market coverage and serve a more diverse customer base[58]. - The company plans to continue focusing on market expansion and new product development as part of its strategic initiatives moving forward[118]. Community and Social Responsibility - The group is committed to ethical behavior and social responsibility, prioritizing environmental sustainability and community engagement[64]. - The group has collaborated with the Hong Kong government to enhance community healthcare services, including seasonal flu vaccination funding and chronic disease management programs[59]. - The expansion of the "Injury Employee Rehabilitation Pilot Program" has led to positive outcomes, benefiting employees injured at work across various industries[37]. - The successful rehabilitation pilot program has increased the return-to-work rate for injured employees, demonstrating the effectiveness of the group's rehabilitation measures[40]. Human Resources - The diverse team of 484 healthcare professionals ensures comprehensive and customer-focused medical and healthcare services[54]. - The group plans to focus on recruiting specialized healthcare professionals to expand its specialized medical services[63]. - As of December 31, 2024, the group had 388 full-time employees and 377 part-time employees, showing a slight increase in full-time staff from 386 the previous year[82]. Investments and Acquisitions - The group has entered into an agreement to acquire 75% of the issued share capital of Youde Dental Clinic Limited for HKD 38,850,000, which will be consolidated into the group's financial statements upon completion[85]. - The limited partnership agreement has been extended to December 31, 2024, and further to June 30, 2025, to enhance business development opportunities in China[78]. - The investment in the limited partnership is recorded at fair value, with a fair value of approximately HKD 58.7 million as of December 31, 2024, representing about 5.7% of the total assets of the group[75]. Governance and Compliance - The group has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions except for the separation of the roles of Chairman and CEO[89]. - The company has adopted the standard code of conduct for securities trading by directors, confirming compliance for the fiscal year 2025[91]. Share Options and Equity - As of December 31, 2024, a total of 3,200,000 options have been granted under the share option plan, with 150,000 options remaining unexercised[94]. - The total number of share options and share rewards that can be granted under the plans is capped at 37,955,223 shares, representing approximately 10% of the issued shares as of the adoption date[99]. - The company has not granted any share options or rewards that require performance targets to be met prior to exercise[100]. - The company has not recognized any stock option expenses for the six months ended December 31, 2024, consistent with the previous period[187].

Financial Performance - The group's revenue for the six months ended December 31, 2024, was approximately HKD 315.8 million, an increase of about HKD 20.6 million or 7.0% compared to the same period in 2023[4]. - The profit attributable to the company's owners for the six months ended December 31, 2024, was approximately HKD 16.8 million, a decrease of about HKD 3.2 million or 16.0% compared to the same period in 2023[4]. - Excluding fair value changes of financial assets and investment properties, the profit attributable to the company's owners was approximately HKD 22.0 million, an increase of about HKD 2.9 million or 15.0% compared to the same period in 2023[4]. - Basic earnings per share for the six months ended December 31, 2024, were approximately HKD 0.044, compared to HKD 0.053 for the same period in 2023[4]. - The total comprehensive income for the period was HKD 15.3 million, down from HKD 17.1 million in the same period last year[5]. - The group's gross profit for the six months ended December 31, 2024, was HKD 148.7 million, compared to HKD 140.5 million in the same period last year[5]. - Administrative and other expenses for the six months ended December 31, 2024, were HKD 128.9 million, compared to HKD 122.0 million in the same period last year[5]. - Adjusted profit before tax for the six months was HKD 20,066,000, down from HKD 23,934,000, indicating a decrease of 16.5%[16]. - The net profit for the period was HKD 16,822,000, compared to HKD 20,033,000 in the previous year, reflecting a decline of 16.5%[16]. - The attributable profit to the company's owners was approximately HKD 16.8 million in FY2025, a decrease of about HKD 3.2 million or 16.0% compared to FY2024[48]. Revenue Breakdown - The segment revenue from general medical services was HKD 206,609,000, up from HKD 198,929,000, reflecting a growth of 3.4%[16]. - The segment revenue from specialist medical services increased to HKD 81,256,000 from HKD 65,152,000, representing a significant growth of 24.7%[16]. - The segment revenue from dental services decreased to HKD 27,923,000 from HKD 31,109,000, a decline of 10.5%[16]. - Comprehensive medical services revenue was HKD 315,788,000, with general medical services contributing HKD 206,609,000 and specialist medical services contributing HKD 81,256,000, reflecting growth in both categories[17]. - The primary care division recorded a revenue increase of approximately 3.9% compared to the same period in the previous fiscal year[54]. - The specialist medical division generated revenue of approximately HKD 81.3 million, representing a year-on-year growth of about 24.7%[57]. - The dental services revenue decreased to approximately HKD 27.9 million from HKD 31.1 million in the same period last year, reflecting market challenges[59]. Assets and Liabilities - Non-current assets as of December 31, 2024, totaled HKD 419.3 million, a decrease from HKD 442.8 million as of June 30, 2024[6]. - Current assets as of December 31, 2024, amounted to HKD 610.5 million, compared to HKD 613.6 million as of June 30, 2024[6]. - Total liabilities as of December 31, 2024, were HKD 193.4 million, an increase from HKD 215.8 million as of June 30, 2024[6]. - Non-current liabilities totaled HKD 73,887,000, an increase from HKD 65,084,000, representing a rise of 13.5%[16]. - Total equity increased slightly to HKD 771,370,000 from HKD 766,666,000, showing a growth of 0.8%[16]. - As of December 31, 2024, the group's net current assets amounted to approximately HKD 417.1 million, an increase from HKD 397.8 million as of June 30, 2024[87]. - The group's interest-bearing bank borrowings were approximately HKD 28.5 million as of December 31, 2024, down from HKD 31.5 million as of June 30, 2024[87]. - The group's capital liability ratio was approximately 3.6% as of December 31, 2024, compared to 4.0% as of June 30, 2024[88]. Operational Efficiency and Strategy - The company continues to focus on optimizing operational efficiency through cost management measures and digital capabilities, enhancing customer experience and expanding market coverage[52]. - The group emphasizes digital transformation initiatives as a cornerstone for enhancing patient care standards and operational efficiency[76]. - The group focuses on customer satisfaction and service excellence through continuous improvement measures and facility upgrades[66]. - The group is committed to strategic measures to solidify its position as a leading provider of quality healthcare services amidst changing medical demands and economic uncertainties[82]. - Continued focus on digitalization aims to strengthen customer engagement, operational efficiency, and healthcare service standards through the integration of digital tools and platforms[83]. Acquisitions and Investments - The company agreed to acquire 75% of the issued share capital of a dental clinic for HKD 38,850,000, which will be consolidated into the group's financial statements upon completion[31]. - The acquisition of Youde Dental Clinic Limited is expected to enhance the company's position and service scope in the dental services market[59]. - The group has no significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the fiscal year 2025[93]. Corporate Governance and Compliance - The company has confirmed compliance with the corporate governance code, with all applicable provisions adhered to for the fiscal year 2025[105]. - The company's audit committee and management have reviewed the unaudited interim results for the fiscal year 2025, discussing internal controls and financial reporting matters[114]. Community Engagement and Social Responsibility - The group has been actively collaborating with the Hong Kong government to enhance community healthcare services, including initiatives like seasonal flu vaccination subsidies and chronic disease management programs[77]. - In the second half of the fiscal year 2025, the group aims to further improve the accessibility and quality of healthcare services provided to the community through ongoing participation in government-led projects[78]. - The group has been recognized for its commitment to sustainability and corporate social responsibility, reinforcing its leadership position in the healthcare industry[67]. Employee and Workforce Management - The group employs a diverse team of 484 healthcare professionals, ensuring comprehensive and customer-centric medical and health services[73]. - As of December 31, 2024, the group had 388 full-time employees and 377 part-time employees, showing a slight increase in full-time staff from 386 in the previous year[102]. - The company has implemented a careful recruitment policy based on market conditions and business needs, focusing on professional healthcare staff[103].

Financial Performance - The total revenue for the fiscal year 2024 decreased due to reduced demand for services related to COVID-19, but overall financial performance showed actual growth compared to pre-pandemic benchmarks[7]. - For the fiscal year 2024, the company reported total revenue of approximately HKD 590.8 million, a decrease of about 41.0% compared to HKD 1,001.7 million in fiscal year 2023[14]. - The revenue from primary care services decreased by approximately HKD 420.7 million or 51.4% to about HKD 398.4 million, primarily due to a reduction in revenue from COVID-19 related services[15]. - The revenue from specialty medical services increased by approximately HKD 18.5 million or 16.1% to about HKD 134.0 million, driven by an increase in patient visits and average spending per visit[16]. - The company's net profit for the fiscal year 2024 decreased to approximately HKD 24.2 million, down about 156.6 million from HKD 180.8 million in fiscal year 2023, resulting in a net profit margin of approximately 4.1% compared to 18.1% in the previous year[24][25]. - The company's attributable profit for the fiscal year 2024 was approximately HKD 24.2 million, a decrease of about 84.3% from HKD 180.8 million in fiscal year 2023, primarily due to a decline in demand for COVID-19 related services[25]. - Gross profit decreased by approximately HKD 323.4 million or 54.5% to about HKD 270.0 million, with a gross margin dropping from 59.2% in fiscal year 2023 to 45.7% in fiscal year 2024[18]. - The gross margin for primary care services fell from 64.0% to 53.3%, while specialty medical services saw a decline from 36.8% to 24.9%[19][20]. - Other income and net gains increased by approximately HKD 26.8 million to about HKD 30.2 million, primarily due to changes in fair value of financial assets and increased bank interest income[21]. - Administrative and other expenses decreased by approximately HKD 84.0 million or 24.1% to about HKD 264.0 million, attributed to reductions in marketing expenses and depreciation[22]. Strategic Initiatives - The company aims to establish a leading position in the healthcare industry through strategic investments in digital transformation and service network expansion[7]. - The company is committed to enhancing its primary healthcare services by expanding its medical center network and service offerings[8]. - The company is focused on creating a sustainable foundation for growth despite the uncertain business environment and challenges in the Greater Bay Area healthcare sector[7]. - The company is actively pursuing excellence in operations and efficiency to mitigate challenges and enhance its market share[7]. - The company plans to explore various investment and acquisition opportunities to create value for stakeholders[12]. - The company aims to enhance healthcare services, focusing on expanding ophthalmic care and improving the efficiency of day surgery centers[12]. - The company will continue to expand its medical center network through new establishments or strategic acquisitions to solidify its position as a comprehensive healthcare service platform[51]. - The company is committed to enhancing digital transformation initiatives to improve customer experience and operational efficiency[48]. - The company is focused on corporate social responsibility, emphasizing ethical behavior, environmental sustainability, and community engagement[46]. Service Expansion - The company expanded its ophthalmic care services with the opening of the POLYEYE Eye Center, providing various eye-related treatments and vision correction services[9]. - The development of the flagship health center, H2, has made significant progress, offering a wide range of medical services including specialized medical care and community pharmacies[10]. - The flagship health center, H2, offers a wide range of specialized medical services and aims to provide convenient access to various healthcare solutions for individuals[36]. - The company opened two new medical centers in Lam Tin and Ngau Tau Kok in fiscal year 2024, expanding its comprehensive healthcare service coverage[28]. - The group operates 61 medical centers, including 1 day surgery center, 3 retail centers, and 1 community pharmacy, as part of its environmental, social, and governance report[192]. Market Dynamics - The company is focused on integrating advanced technology and data analytics to significantly impact individual and societal well-being[79]. - The company faces strategic risks due to rapidly changing community demands and ongoing global economic uncertainties post-pandemic[135]. - The company relies on its professional medical team, and any failure to recruit or retain qualified personnel may adversely affect financial performance[136]. - The company emphasizes the importance of maintaining good relationships with suppliers to ensure long-term sustainable development[141]. - The increasing demand for medical beauty services reflects changing consumer preferences and desires, providing favorable conditions for the group to capture market opportunities[39]. Governance and Compliance - The company has adopted the corporate governance code as per the Stock Exchange's listing rules, ensuring compliance and best practices[77]. - The board includes experienced professionals with a track record in various industries, contributing to strategic decision-making[68][70]. - The company has established mechanisms to ensure the board receives independent views and opinions, which have been reviewed and deemed effective[88]. - The company has implemented training and continuous professional development for directors and senior management[81]. - The board has authorized committees to handle specific governance responsibilities, ensuring effective oversight[81]. - The company has confirmed compliance with the disclosure requirements for related party transactions as per the listing rules[157]. Shareholder Engagement - The company maintains a shareholder communication policy to ensure timely access to information, allowing shareholders to exercise their rights and participate actively[121]. - The company encourages shareholders to submit inquiries or suggestions via its website or designated contact methods[124]. - The board will review the dividend policy annually to provide stable and sustainable returns to shareholders while retaining sufficient reserves for future growth[123]. - The company’s articles of association allow shareholders holding at least 10% of the paid-up capital to request a special general meeting within two months of submission[120]. Human Resources - The group has 388 full-time employees and 355 part-time employees as of June 30, 2024, a decrease from 428 full-time and 426 part-time employees in the previous year[62]. - The company has a competitive compensation policy for senior management, with 1 member earning between HKD 0 to 3,000,000, 4 members earning between HKD 3,000,001 to 6,000,000, and 1 member earning between HKD 6,000,001 to 9,000,000 for the fiscal year 2024[151]. - The company’s compensation structure includes fixed, performance-related, and long-term incentives to attract and retain high-quality employees[151]. Environmental, Social, and Governance (ESG) - The environmental, social, and governance (ESG) report is based on a comprehensive stakeholder engagement process and materiality assessment[193]. - The board of directors oversees all ESG-related matters and is responsible for monitoring and managing the group's sustainability performance[198]. - The ESG committee was established in the fiscal year 2020 to assist the board in managing and addressing all ESG issues[199]. - The group has committed to developing new environmental goals for the next three years, enhancing its corporate social responsibility[198]. - The report adheres to the ESG reporting guidelines as per the listing rules, ensuring compliance and transparency[194].

Financial Performance - The group's revenue for the fiscal year 2024 was approximately HKD 590.8 million, a decrease of about 41.0% compared to fiscal year 2023, primarily due to a reduction in revenue from COVID-19 related services by approximately HKD 509.0 million[1]. - The profit attributable to the company's owners for fiscal year 2024 was approximately HKD 24.2 million, a decrease of about HKD 156.6 million or 86.6% compared to fiscal year 2023[1]. - The basic earnings per share for fiscal year 2024 was approximately HKD 0.064, down from HKD 0.476 in fiscal year 2023[2]. - The total comprehensive income for the year was HKD 19.2 million, significantly lower than HKD 180.1 million in the previous year[2]. - The adjusted profit before tax for the group is HKD 26,564,000 in 2024, compared to HKD 238,816,000 in 2023, representing a decline of approximately 89%[13]. - The group reported a net profit of HKD 24,189,000 for 2024, a significant drop from HKD 180,839,000 in 2023, indicating a decline of around 87%[13]. - The income tax expense decreased from approximately HKD 58.0 million in FY2023 to about HKD 2.4 million in FY2024, resulting in a drop in the effective tax rate from approximately 24.3% to about 8.9%[41]. - Net profit for the year decreased from approximately HKD 180.8 million in FY2023 to about HKD 24.2 million in FY2024, with net profit margins of approximately 4.1% and 18.1% respectively[42]. Revenue Breakdown - The external customer revenue for the general medical services segment is HKD 398,388,000 in 2024, down from HKD 819,067,000 in 2023, indicating a decrease of about 51%[13]. - The revenue from primary healthcare services decreased by approximately HKD 420.7 million or 51.4% to about HKD 398.4 million in fiscal year 2024[33]. - The revenue from specialist medical services increased by approximately HKD 18.5 million or 16.1% to about HKD 134.0 million in fiscal year 2024[33]. - Comprehensive medical service revenue for 2024 was HKD 590,819,000, with general medical services contributing HKD 398,388,000 and specialist services contributing HKD 192,431,000[17]. Assets and Liabilities - Non-current assets totaled HKD 442.8 million for fiscal year 2024, down from HKD 466.5 million in fiscal year 2023[3]. - Current assets decreased to HKD 613.6 million in fiscal year 2024 from HKD 797.0 million in fiscal year 2023[3]. - The total assets of the group decreased to HKD 1,056,373,000 in 2024 from HKD 1,263,486,000 in 2023, a reduction of about 16%[14]. - The total liabilities for the group in 2024 are HKD 289,707,000, down from HKD 455,269,000 in 2023, reflecting a decrease of approximately 36%[14]. - Current liabilities were reduced to HKD 215.8 million in fiscal year 2024 from HKD 349.2 million in fiscal year 2023[3]. - The total equity attributable to the company's owners was HKD 766.7 million, down from HKD 808.2 million in fiscal year 2023[4]. Cost Management - Total costs of services provided were HKD 320,968,000 in 2024, down from HKD 408,510,000 in 2023, reflecting a cost reduction strategy[22]. - The cost of services provided decreased by approximately HKD 87.5 million or 21.4% to about HKD 321.0 million in fiscal year 2024[34]. - Administrative and other expenses decreased by approximately HKD 84.0 million or 24.1% from about HKD 348.0 million in FY2023 to approximately HKD 264.0 million in FY2024, mainly due to reductions in marketing expenses, depreciation, and impairment losses[38]. Dividends - The board proposed a final dividend of HKD 0.028 for fiscal year 2024, compared to HKD 0.16 for fiscal year 2023[1]. - The final dividend is subject to approval at the upcoming annual general meeting scheduled for December 2, 2024[77]. Operational Developments - The company focused on cost management and operational efficiency improvements while investing in IT infrastructure and digital capabilities to enhance customer experience and market coverage[45]. - The primary care division's overall revenue increased by approximately 28.5% in FY2024 compared to FY2023, excluding pandemic-related services[46]. - Patient visits in the primary care division rose by about 20.6% in FY2024 compared to FY2023, demonstrating resilience in meeting general healthcare demands[46]. - The company opened two new medical centers in FY2024, located in Lam Tin and Ngau Tau Kok, expanding its comprehensive healthcare service coverage[46]. - The introduction of specialized eye care services at the POLYEYE Eye Center aims to address various eye conditions and enhance the company's capabilities in ophthalmology[47]. Strategic Initiatives - The group is focusing on strategic investment in biomedical technology, particularly in developing gut microbiome technology based on precision medicine[52]. - The introduction of the "Ying Jian Online Store" membership program has improved brand awareness and customer loyalty, expanding market share[54]. - The "H2 Rewards" mobile app membership program has become a valuable asset for fostering customer relationships and encouraging active participation[55]. - The group aims to create value for stakeholders through continuous updates and enhancements of its products and services[53]. Corporate Social Responsibility - The company remains committed to corporate social responsibility by collaborating with the Hong Kong government to promote sustainable healthcare development[50]. - The group emphasizes the importance of corporate social responsibility and has been recognized for its contributions to community welfare[57]. Future Outlook - The company maintains a cautiously optimistic outlook for business growth and financial performance in the next fiscal year despite ongoing global economic uncertainties[61]. - The company aims to diversify its revenue sources through strategic partnerships, acquisitions, and market analysis to expand its customer base[61]. - The company is committed to digital transformation initiatives to enhance customer experience and operational efficiency, focusing on optimizing supply chains and data-driven decision-making[61].